Compare Globus Medical Inc. Class A Common Stock (GMED) vs Keysight Technologies Inc (KEYS) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Keysight Technologies (KEYS) trades at $370.22, down 1.98% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $3.07 exceeding expectations, and maintains solid profitability with a net income margin of 19.14%. Recent news highlights growth in AI infrastructure and 6G development, positioning KEYS for future expansion amid accelerating demand.

The investment outlook for KEYS is positive, driven by earnings momentum and strategic positioning in high-growth areas like AI and 6G. Key risks include elevated valuation multiples and potential supply constraints, but analyst consensus targets $421.29, suggesting ~14% upside from current levels based on strong fundamentals and institutional support.